Shares of Revance Therapeutics, Inc. ( NASDAQ:RVNC – Get Rating ) have been assigned an average recommendation of 'Moderate Buy' from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $40.09. A number of brokerages recently commented on RVNC.

https://www.dailypolitical.com/2023/03/05/revance-therapeutics-inc-nasdaqrvnc-receives-average-rating-of-moderate-buy-from-analysts.html

#dailypolitical